Replies to post #196995 on Biotech Values

[biocqr]

LOXO > data/scans slide deck...

Clinical safety and activity from a Phase 1
study of LOXO-101, a selective TRKA/B/C inhibitor,
in solid-tumor patients with NTRK gene fusions

https://ir.loxooncology.com/docs/presentations/EORTC_LOXO101.pdf

[poorgradstudent]

LOXO:

They should be careful reporting 100% response rates. You can only go down from there, and then the market will be greatly disappointed!

Nice results though. I still think LOXO and RXDX can be part of a basket as I'm not clear which approach is better. Both seem to be producing numerically high response rates.